To compare late genitourinary (GU) and gastrointestinal (GI) toxicity of radiotherapy (RT) to localized fields for prostate cancer delivered using intensity-modulated RT (IMRT) versus conventional RT (ConvRT). The records of 461 patients were reviewed; 355 patients received IMRT and 106 received ConvRT. Late GU and GI toxicity were compared. Late GU toxicity rates were not significantly different (P ¼ 0.166); however, late GI toxicity rates were lower with IMRT (P ¼ 0.001). Regression analyses demonstrated that only IMRT use (P ¼ 0.006) predicted reduction in late GI toxicity but no factors correlated with late GU toxicity. IMRT did not influence late GU toxicity but was associated with a reduction of late GI toxicity over ConvRT.
Introduction
External beam radiotherapy (EBRT) is one of the several options available for successful treatment of early prostate cancer, and has recently undergone significant changes. 1, 2 The transition from cobalt units to megavoltage linear accelerators, coupled with the development of the rotating gantry and resulting ability to perform isocenter-based treatment planning, enabled incremental precision in the delivery of radiation. Later, the integration of computed tomography (CT) into the radiotherapy (RT) planning process permitted the development of conformal therapy, typically delivered using six-field technique. 3 A major recent development in RT is intensity-modulated RT (IMRT), which involves approaching the treatment optimization as a solution to an 'inverse' problem. [4] [5] [6] IMRT became a viable approach when hardware and software delivery systems improved in parallel with increased computer speed.
IMRT is achieving increasingly widespread use in prostate RT; however, clinical comparison data of IMRT to prior techniques are still somewhat scant. Most reports of IMRT for prostate are single-institution studies, which have demonstrated the feasibility of high-dose IMRT. [7] [8] [9] [10] [11] [12] [13] [14] [15] Some have explored dosimetric, cancer control and/or toxicity comparisons between IMRT and conformal therapy and have suggested reduced toxicity with the use of IMRT compared to conventional therapy. [9] [10] [11] [12] Of note, prior IMRT toxicity outcome comparisons have been reported with patients treated in the prone position with or without a rectal balloon for prostate immobilization, or with IMRT delivered using tomotherapy. To date, no institution has documented outcomes (as compared with those obtained using conventional RT (ConvRT) at the same institution) for patients treated in the supine position with step-and-shoot coplanar-beam IMRT, the most common implementation of prostate IMRT. Many consortium (Radiation Therapy Oncology Group (RTOG), Cancer and Leukemia Group B and European Organization for Research and Treatment of Cancer) studies do allow the use of IMRT, but often simply permit IMRT to replace conventional conformal therapy and do not explore IMRT-specific issues. Additionally, some institutions have recently explored the role of IMRT in the setting of hypofractionation without comparison to conventional techniques at the same institution. 14, 15 Data on the benefit of the use of IMRT are critically important if we are to understand the dosimetric and clinical tradeoffs of IMRT over conventional techniques and to design future technical and clinical studies. Herein, we provide a single-institutional experience of the use of IMRT compared to ConvRT in an effort to determine the impact of IMRT on late gastrointestinal (GI) and genitourinary (GU) toxicity (defined as toxicity occurring X120 days after treatment).
Methods
The charts of 610 consecutive prostate cancer patients who were treated with EBRT from 1998 to 2005 and for whom demographic, treatment and follow-up information were available were identified. The following groups of patients were excluded: (a) patients receiving brachytherapy as any component of their treatment, (b) patients receiving whole pelvic RT, (c) patients receiving IMRT for only a portion of their treatment and (d) patients who had less than 120 days of follow-up available. Groups (a) and (b) were excluded because they were expected to have different toxicity profiles from those treated to localized fields with EBRT. Group (c) was excluded because on these patients the treatment plans were generated for the different phases of therapy using different planning systems and could not be reliably composited for dosimetric analysis. Group (d) was excluded as the focus of the investigation was analysis of late, not early, toxicity. The remaining 461 patients comprise the database for the current analysis. This cohort was divided into patients receiving ConvRT (four-or six-field therapy) (355 patients) versus IMRT (106 patients).
Patients receiving hormone therapy were allowed in the study. Hormone therapy, typically administered in more recent years for patients with adverse prognostic factors, consisted of a combination of testosterone receptor antagonist (flutamide or bicalutamide) and a GnRH agonist (leuprolide or goserelin); 16 duration of hormone therapy was 4 months to 2 years.
The patients were simulated and treated in the supine position. A retrograde urethrogram was performed, and bladder and rectal contrast were used; no intravenous contrast was used. A planning CT scan was performed in the treatment position using a flat table insert. The patients were scanned from the top of L5 to 5 cm below the ischial tuberosities using 3 mm slice thickness. The prostate, seminal vesicles and normal structures were manually contoured on the planning CT using AcQSim VoxelQ software (Philips Medical Systems, Cleveland, OH, USA). The rectum and bladder were outlined according to the RTOG guidelines; 17, 18 specifically, the rectum was contoured from the level of the ischial tuberosities (lower border) to the rectosigmoid junction (upper border) and the bladder was contoured in its entirety from apex to base. The initial clinical target volume (CTV 1 ) was defined as the prostate and seminal vesicles and was expanded uniformly by 1 cm to define the planning target volume (PTV 1 ) which was treated to 50.0-50.4 Gy in 1.8-2.0 Gy fractions. This initial phase was followed by a boost phase of treatment to the prostate alone (CTV 2 ) to achieve a final dose of 64.8-76.4 Gy. For the ConvRT patients, PTV 2 was defined as CTV 2 þ 1 cm, and rectal blocks were used on the lateral fields for the four-field and six-field boost plans after 60 Gy. For the IMRT patients, PTV 2 was defined as CTV 2 þ 1 cm, except at the prostate/rectal interface where the expansion was 0.6 cm. 18 MV photons were used for the four-field and six-field plans, and 6 MV photons were used for the IMRT plans, with 1.8 or 2.0 Gy fractions delivered once daily.
All patients were treated on a Varian 2100 EX linear accelerator (Varian Medical Systems, Palo Alto, CA, USA). The four-field and six-field treatments, both for the initial and for the boost phases, were planned using PlanUNC. 19 The IMRT plans were generated using Corvus inverse planning system (Nomos Corp., Sewickley, PA, USA), and were delivered using a stepand-shoot, multi-leaf collimator-based technique. A seven-field arrangement was typically used for IMRT, with constraints imposed on the mid-and high-dose levels on the bladder and rectum dose-volume histograms. The goal for the treatment in all cases was to cover the PTV with the prescription dose. Dosimetric parameters were reviewed from the dosevolume histograms for the normal structures and for the target. Specifically, the rectum/bladder V30 (percent of the structure receiving 30 Gy or more), V40, V50, V60 and V70 were tabulated. RTOG toxicity scores (late GI and late GU) were assigned based on standard scales. 20 These toxicity scores were assigned by the physician at each follow-up visit. Toxicity rates were tabulated for each general category of analysis and compared using the w 2 test. 21 Then, as a more stringent measure of evaluating the treatment factors influencing toxicity, for each general category of analysis, an ordered logit regression 22, 23 was performed using all major disease and treatment factors as covariates. Table 1 summarizes the patient demographic, disease and treatment factors. As demonstrated, the groups were Comparison of late GI and GU toxicity of RT AB Jani et al generally balanced, except for the higher grade and higher final dose in the IMRT group. Also, the IMRT group had a lower percentage of T3/T4 patients; because these locally advanced patients were treated with whole pelvis RT (an exclusion criteria in our study, as described in the Methods section) in recent years, only a small number of T3/T4 patients in our study were treated with localized fields using IMRT. The bladder and rectum dose-volume histogram end points were lower at every dose level for IMRT compared with ConvRT. Table 2 displays the results of the toxicity analysis for (a) late GU and (b) late GI. As displayed, there was no significant difference (P ¼ 0.166) between the IMRT and ConvRT groups with regard to late GU toxicity. However, there was a substantial reduction (Po0.001) in late GI toxicity in the IMRT group, particularly grade 1 toxicity. These results support the hypothesis that toxicity rates were lower in the IMRT group owing to the mid-to high-dose range rectal dosimetric end points (V40, V50, V60 and V70) being lower than in the ConvRT group.
Results
This hypothesis is further bolstered by Table 3 , which displays the results of the ordered logit regression for (a) late GU toxicity and (b) late GI toxicity. As shown, no factors reached statistical significance on regression analysis of late GU toxicity, and only IMRT use (P ¼ 0.006) reached significance on the corresponding analysis of late GI toxicity. Thus, only IMRT use emerged as a factor significant in GI toxicity reduction, likely owing to the improved rectal dosimetric outcomes described above. Comparison of late GI and GU toxicity of RT AB Jani et al
Conclusions
IMRT represents the most widely adopted new technology to improve prostate cancer radiation treatment planning and delivery. Analysis of RT toxicity becomes increasingly important in prostate cancer as delivered doses increase and as new technologies are introduced and implemented.
The results of our investigation indicate that there were no significant differences in late GU toxicity with the use of IMRT. Although IMRT treatment planning resulted in lower bladder dose, as demonstrated in Table 1 , the lack of difference in observed rate of GU toxicity may relate to similarities in urethral dose, which was not specifically constrained, between the IMRT and ConvRT approaches. In contrast, late GI toxicity was significantly reduced, and this finding suggests that the reduction in rectal dose afforded by IMRT, particularly the higher dose levels shown in Table 1 , translated to lower late GI toxicity rates. Further support of the hypothesis that IMRT reduced late GI but not GU toxicity is displayed in Table 3 , which shows that IMRT use was the only variable reaching statistical significance on regression analysis for late GI toxicity, but no factor reached significance in the corresponding analysis for late GU toxicity.
Additional support of the role of IMRT in influencing toxicity rates is shown in Tables 4 and 5. Table 4 displays  the patient characteristics and Table 5 displays the late GI and late GU toxicity rates for a group of 41 patients (who were excluded from the original analysis) receiving IMRT for only a portion of their treatment (ranging from 6 to 24 Gy of the total dose). This cohort of 41 patients defines an 'intermediate' group. As shown, the rates of toxicity in this 'intermediate' group are intermediate to those found in the ConvRT and IMRT groups in Table 2 ; specifically, the late GI toxicity rates are intermediate between ConvRT and IMRT, and the late GU toxicity rates are similar to both ConvRT and IMRT in Table 2 . Because this 'intermediate' group was small in size and had combined treatment techniques which prohibits dosimetric analysis (as described in the Methods section), no statistical analyses were possible on this cohort. However, the intermediate rates of side effects in this group lend further support that IMRT was the major factor influencing late GI toxicity reduction.
Our findings are consistent with other studies that document reduction of GI but not GU toxicity with the use of IMRT. [9] [10] [11] [12] In these prior investigations, patients treated in the prone position demonstrated similar bladder doses using IMRT versus ConvRT. [9] [10] [11] This similarity in bladder dose between IMRT and conventional approaches was also the case with the use of tomotherapy. 12 In our study, however, bladder doses were lower with IMRT but this still did not translate to reduction of late GU toxicity. As described above, this similarity in GU toxicity between IMRT and ConvRT patients likely relates to similarities in prostatic urethral dose with both techniques.
The limitations of the current study, including the biases inherent to a retrospective review, are well understood by the authors. Additionally, the results described herein relate to late toxicity and cannot be extended to early toxicity (i.e. toxicity occurring from start of treatment to 120 days from the end of treatment) -this early toxicity analysis is the subject of an independent investigation at our institution. The biases inherent to physician-based assignment of toxicity scores also warrant consideration in interpretation of the results.
Within these stated limitations, however, the current study provides valuable single-institution data on the impact of IMRT on late toxicity, which suggest that a reduction in late GI toxicity is associated with IMRT use. The results are important, as they represent the first-ever reported reduction of GI toxicity with the use of stepand-shoot IMRT delivered in the supine position, the most common implementation of prostate IMRT. The results are also important in the context of the relative dose escalation that occurred throughout the course of the study, suggesting that IMRT can reduce GI toxicity over conventional techniques even with higher doses. The results of the current study can be used as the basis for further exploration of IMRT in the multiinstitutional and/or prospective setting. ), severe hemorrhagic cystitis. GI: Grade 0: none; grade 1: mild diarrhea, mild cramping, bowel movement five times daily, slight rectal discharge or bleeding; grade 2: moderate diarrhea and colic, bowel movement 45 times daily, excessive rectal mucus or intermittent bleeding; grade 3: obstruction or bleeding requiring surgery; grade 4: necrosis, perforation, fistula.
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